Ana RadeljevicFounder & CEO at Adventus Partners
Ana is a life science executive with extensive experience in strategic and business planning, finance, business development and operations. She held roles of increasing responsibility at Sanofi and Genzyme Corp. and most recently was VP of FP&A at PerkinElmer. While at Genzyme, Ana worked in corporate finance and supported BD and special projects for the office of CFO, such as divestiture of Genetic Testing, Diagnostics and Pharmaceuticals businesses, issuance of $1.0 billion in corporate debt and acquisition negotiations and Genzyme sale to Sanofi. At Sanofi, she led global forecasting for Renal and Biosurgery businesses and headed business planning and BD for Biosurgery working on acquisition of Pluromed, leading strategic efforts to maximize global commercial value of the portfolio and led divestiture of Cell Therapy and Regenerative Medicines business to Vericel. Ana started her career with Deloitte in audit and subsequently valuation practice. Ana received her MBA from Syracuse University and holds CPA and CFA designations.